AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1650106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of sydnocarb and incazane
Number of subjects: 0
Study 1650106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of pimozide and incazane
Number of subjects: 0
Study 1650106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone test, response to psychostimulants, and diazepam test
Number of subjects: 0
Study 31738070 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Forced-Choice (MFC) format
Number of subjects: 593
Study 31738070 — intervention group
Group type: COMPARATOR
Intervention: Rating Scale (RS) format
Number of subjects: 593
Study 31738070 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MFC and RS formats
Number of subjects: 593
Study 31738070 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC format
Number of subjects: 593
Study 31738070 — intervention group
Group type: COMPARATOR
Intervention: RS format
Number of subjects: 593
Study 30782097 — intervention group
Group type: EXPERIMENTAL
Intervention: Adzuki bean extract
Number of subjects: 0
Study 30782097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27578271 — intervention group
Group type: EXPERIMENTAL
Intervention: SEE IT training
Number of subjects: 50
Study 27578271 — intervention group
Group type: COMPARATOR
Intervention: Consensus coder ratings
Number of subjects: 50
Study 27578271 — intervention group
Group type: COMPARATOR
Intervention: SP ratings
Number of subjects: 50
Study 26505801 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse group (n=11)
Number of subjects: 24
Study 26505801 — intervention group
Group type: COMPARATOR
Intervention: Relapse-free group (n=13)
Number of subjects: 24
Study 26505801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (n=24)
Number of subjects: 24
Study 26505801 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse-risk assessment model
Number of subjects: 24
Study 23374372 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy in addition to diet therapy (n = 26)
Number of subjects: 51
Study 23374372 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency exercise subgroup
Number of subjects: 51
Study 23374372 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy alone (n = 25)
Number of subjects: 51
Study 21225293 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg rocuronium
Number of subjects: 24
Study 21225293 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg rocuronium
Number of subjects: 24
Study 21225293 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium 1.5 mg/kg
Number of subjects: 24
Study 19709328 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (GM)
Number of subjects: 94
Study 19709328 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (AK)
Number of subjects: 94
Study 17228345 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (1.5 l/day)
Number of subjects: 28
Study 17228345 — intervention group
Group type: COMPARATOR
Intervention: Meat (250 g/day)
Number of subjects: 28
Study 14732826 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to hemodialysis guidelines and modifiable practices (dialysis dose, phosphate control, improved anemia, partial correction of serum albumin, reduced interdialytic weight gain, less use of catheters for vascular access)
Number of subjects: 0
Study 14732826 — intervention group
Group type: COMPARATOR
Intervention: Having albumin <3.5 g/dl
Number of subjects: 0
Study 11601598 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood victimization (abuse and neglect)
Number of subjects: 582
Study 9842820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metoprolol (maximal dose of 10 mg)
Number of subjects: 150
Study 9842820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 9842820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic glycopyrrolate (maximal dose of 6 microg/kg)
Number of subjects: 150
Study 8128188 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cM-T412
Number of subjects: 29
Study 8128188 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg cM-T412
Number of subjects: 29
Study 8128188 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg cM-T412
Number of subjects: 29
Study 8128188 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 29
Study 2569998 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine three times daily
Number of subjects: 20
Study 2569998 — intervention group
Group type: COMPARATOR
Intervention: 4 mg chlorpheniramine three times daily
Number of subjects: 20
Study 406623 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking one cigarette
Number of subjects: 25
Study 406623 — intervention group
Group type: COMPARATOR
Intervention: Control (no smoking)
Number of subjects: 25
Study 31292172 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade (PVB)
Number of subjects: 69
Study 31292172 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural blockade (TEB)
Number of subjects: 69
Study 29188883 — intervention group
Group type: EXPERIMENTAL
Intervention: DASHNa-CC intervention (usual care plus dietary intervention)
Number of subjects: 60
Study 29188883 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 25985245 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided therapy with adalimumab (ADA)
Number of subjects: 20
Study 25985245 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 20
Study 24034093 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil plus statins
Number of subjects: 156
Study 24034093 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 156
Study 21214940 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc (monthly IPTc with a single dose of sulphadoxine/pyrimethamine (SP) plus three doses of amodiaquine (AQ))
Number of subjects: 1277
Study 21214940 — intervention group
Group type: COMPARATOR
Intervention: Control (SP and AQ placebos)
Number of subjects: 1277
Study 21214940 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc
Number of subjects: 1277
Study 21214940 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1277
Study 18647310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 20
Study 18647310 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 20
Study 16478746 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa every 3 weeks (500-microg dose)
Number of subjects: 705
Study 16478746 — intervention group
Group type: COMPARATOR
Intervention: Weekly darbepoetin alfa (2.25-microg/kg)
Number of subjects: 705
Study 16478746 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa every 3 weeks
Number of subjects: 705
Study 16478746 — intervention group
Group type: COMPARATOR
Intervention: Weekly darbepoetin alfa
Number of subjects: 705
Study 12777459 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐pertechnetate salivary gland scintigraphy with semiquantitative analysis
Number of subjects: 21
Study 10843975 — intervention group
Group type: EXPERIMENTAL
Intervention: UMC (University‐affiliated county medical center)
Number of subjects: 200
Study 10843975 — intervention group
Group type: EXPERIMENTAL
Intervention: UMC
Number of subjects: 200
Study 10843975 — intervention group
Group type: COMPARATOR
Intervention: HMO
Number of subjects: 200
Study 10843975 — intervention group
Group type: COMPARATOR
Intervention: UNMH
Number of subjects: 200
Study 9327759 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated diet (16.2% of energy as lauric plus myristic plus palmitic acids)
Number of subjects: 58
Study 9327759 — intervention group
Group type: EXPERIMENTAL
Intervention: High trans diet (6.6% of energy as trans‐monoenes)
Number of subjects: 58
Study 9327759 — intervention group
Group type: COMPARATOR
Intervention: Oleic diet (16.7% of energy as oleic acid)
Number of subjects: 58
Study 9327759 — intervention group
Group type: COMPARATOR
Intervention: Moderate trans diet (3.8% of energy as trans‐monoenes)
Number of subjects: 58
Study 8260564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adrenaline infusions
Number of subjects: 44
Study 8260564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 44
Study 3518773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily + Indomethacin 50 mg twice daily
Number of subjects: 25
Study 3518773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily + Sulindac 200 mg twice daily
Number of subjects: 25
Study 3518773 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 25
Study 3518773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31986942 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal complications (neonatal sepsis)
Number of subjects: 841
Study 31986942 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal complications (IVH/ROP/NEC)
Number of subjects: 841
Study 31986942 — intervention group
Group type: EXPERIMENTAL
Intervention: Low maternal educational score
Number of subjects: 841
Study 31986942 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm delivery <34 weeks
Number of subjects: 841
Study 29469206 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan treatment for 3 months
Number of subjects: 120
Study 27591767 — intervention group
Group type: EXPERIMENTAL
Intervention: reduced-dose/IR
Number of subjects: 200
Study 27591767 — intervention group
Group type: COMPARATOR
Intervention: standard-dose/FBP
Number of subjects: 200
Study 25211164 — intervention group
Group type: EXPERIMENTAL
Intervention: Music enhanced with positive expectancy
Number of subjects: 48
Study 25211164 — intervention group
Group type: COMPARATOR
Intervention: Non-musical sound enhanced with positive expectancy
Number of subjects: 48
Study 25211164 — intervention group
Group type: COMPARATOR
Intervention: No expectancy enhancement (control group)
Number of subjects: 48
Study 25211164 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy-enhanced music (replication cohort)
Number of subjects: 48
Study 23773313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleavage-stage embryo biopsy
Number of subjects: 0
Study 23773313 — intervention group
Group type: COMPARATOR
Intervention: Control (unbiopsied embryos)
Number of subjects: 0
Study 23773313 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst biopsy
Number of subjects: 0
Study 23773313 — intervention group
Group type: COMPARATOR
Intervention: Control (blastocysts)
Number of subjects: 0
Study 21226357 — intervention group
Group type: EXPERIMENTAL
Intervention: Equilibrium pressure pneumatic tourniquet (EPPT)
Number of subjects: 21
Study 21226357 — intervention group
Group type: COMPARATOR
Intervention: Common tourniquet (control group)
Number of subjects: 21
Study 18538574 — intervention group
Group type: EXPERIMENTAL
Intervention: Static progressive stretch using a patient-directed orthosis for a mean of 9 weeks (range, 3 to 27 weeks)
Number of subjects: 41
Study 18538574 — intervention group
Group type: EXPERIMENTAL
Intervention: Static progressive stretch
Number of subjects: 41
Study 15930221 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 47
Study 15930221 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cow's milk formula (MCF) with added cholesterol
Number of subjects: 47
Study 15930221 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk formula (CF)
Number of subjects: 47
Study 15930221 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison at 18 months
Number of subjects: 47
Study 14585532 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bands
Number of subjects: 26
Study 14585532 — intervention group
Group type: COMPARATOR
Intervention: Weightlifting exercises (Koch press)
Number of subjects: 26
Study 11064530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior intervention
Number of subjects: 243
Study 11064530 — intervention group
Group type: COMPARATOR
Intervention: Information groups (pamphlet or extensive information package)
Number of subjects: 243
Study 11064530 — intervention group
Group type: COMPARATOR
Intervention: All groups (Cognitive-behavior and Information groups)
Number of subjects: 243
Study 8821311 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily lithium dosing (700 mg)
Number of subjects: 50
Study 8821311 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day lithium dosing (1200 mg)
Number of subjects: 50
Study 8821311 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 50
Study 1449443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol reduction treatment
Number of subjects: 50000
Study 3937665 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel contraceptive implants (NORPLANT)
Number of subjects: 50
Study 3937665 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine device (Cu T380-Ag)
Number of subjects: 50
Study 3937665 — intervention group
Group type: COMPARATOR
Intervention: Barrier or no contraception
Number of subjects: 50
Study 31219771 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16
Study 31219771 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective β-adrenergic blockade (40 mg propranolol)
Number of subjects: 16
Study 29624942 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing and counseling (HTC) provided by VHTs
Number of subjects: 256
Study 29624942 — intervention group
Group type: COMPARATOR
Intervention: HIV testing and counseling (HTC)
Number of subjects: 256
Study 29624942 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model of FP and HTC
Number of subjects: 256
Study 25123239 — intervention group
Group type: EXPERIMENTAL
Intervention: HXLPE liners
Number of subjects: 54
Study 25123239 — intervention group
Group type: COMPARATOR
Intervention: UHMWPE liners
Number of subjects: 54
Study 23547209 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 283
Study 23547209 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 4 mg/kg
Number of subjects: 283
Study 23547209 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 283
Study 23547209 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (any dose) in open-label extension
Number of subjects: 283
Study 23547209 — intervention group
Group type: COMPARATOR
Intervention: Placebo switched to belimumab 10 mg/kg in extension
Number of subjects: 283
Study 23547209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 21470404 — intervention group
Group type: EXPERIMENTAL
Intervention: K-1 mmol/l
Number of subjects: 24
Study 21470404 — intervention group
Group type: COMPARATOR
Intervention: K+1 mmol/l
Number of subjects: 24
Study 21470404 — intervention group
Group type: COMPARATOR
Intervention: K
Number of subjects: 24
Study 19817753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 54
Study 19817753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids + Vitamin D(3)
Number of subjects: 54
Study 19817753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 16670859 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical support (TM)
Number of subjects: 36
Study 16670859 — intervention group
Group type: COMPARATOR
Intervention: Conventional support and paper diary (PD)
Number of subjects: 36
Study 14872179 — intervention group
Group type: EXPERIMENTAL
Intervention: One injection of varicella vaccine
Number of subjects: 2000
Study 14872179 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of varicella vaccine
Number of subjects: 2000
Study 11434826 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg/kg per day for 5 days (n = 398)
Number of subjects: 795
Study 11434826 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/kg per day for 10 days (n = 397)
Number of subjects: 795
Study 9552998 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk appraisal questionnaire
Number of subjects: 5686
Study 9552998 — intervention group
Group type: COMPARATOR
Intervention: Health questionnaire alone (Control)
Number of subjects: 5686
Study 7913801 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 12
Study 7913801 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 12
Study 3063288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 100 mg daily (Group 1)
Number of subjects: 32
Study 3063288 — intervention group
Group type: COMPARATOR
Intervention: Combination of HCTZ with amiloride (Group 2)
Number of subjects: 32
Study 30893305 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative, normative and monetary incentives
Number of subjects: 0
Study 30893305 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline users
Number of subjects: 0
Study 30893305 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-monetary incentives
Number of subjects: 0
Study 28402745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ularitide (15 ng/kg/min continuous intravenous infusion for 48 hours)
Number of subjects: 2157
Study 28402745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 48 hours)
Number of subjects: 2157
Study 28402745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ularitide
Number of subjects: 2157
Study 28402745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2157
Study 25552906 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (400-1,600 μg, administered twice daily for 21 days)
Number of subjects: 159
Study 25552906 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (single oral 400 mg dose on day 2 or 24)
Number of subjects: 159
Study 23868508 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinyl palmitate per day)
Number of subjects: 0
Study 23868508 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule per day)
Number of subjects: 0
Study 21606533 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin therapy for 12 weeks
Number of subjects: 341
Study 21606533 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin therapy for 24 weeks
Number of subjects: 341
Study 21606533 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin therapy for 12 or 24 weeks
Number of subjects: 341
Study 21606533 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients carrying CC(rs12979860)
Number of subjects: 341
Study 19706351 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-ended pain question
Number of subjects: 207
Study 19706351 — intervention group
Group type: COMPARATOR
Intervention: Closed-ended pain question
Number of subjects: 207
Study 19706351 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up questions
Number of subjects: 207
Study 19706351 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional pain assessment instrument
Number of subjects: 207
Study 16970162 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine drug and Molida therapy (Group A)
Number of subjects: 136
Study 16970162 — intervention group
Group type: COMPARATOR
Intervention: Routine drug only (Group B)
Number of subjects: 136
Study 15496220 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl 5 mg once daily for 15 days
Number of subjects: 19
Study 15496220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline HCl 50 mg once daily for 5 days followed by 100 mg once daily for 10 days
Number of subjects: 19
Study 15496220 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of donepezil HCl and sertraline HCl
Number of subjects: 19
Study 15496220 — intervention group
Group type: COMPARATOR
Intervention: Donepezil HCl only
Number of subjects: 19
Study 15496220 — intervention group
Group type: COMPARATOR
Intervention: Sertraline HCl only
Number of subjects: 19
Study 11061497 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 120
Study 11061497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9051387 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 40
Study 9051387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8113482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual assault prevention program (treatment group)
Number of subjects: 360
Study 8113482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study 2890366 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (primed with 50 micrograms kg‐1)
Number of subjects: 3
Study 2890366 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (control, no priming)
Number of subjects: 3
Study 2890366 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (primed with 10 micrograms kg‐1)
Number of subjects: 3
Study 2890366 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (control, no priming)
Number of subjects: 3
Study 2890366 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (primed with 10 micrograms kg‐1)
Number of subjects: 3
Study 2890366 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (control, no priming)
Number of subjects: 3
Study 31413088 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg iron as ferrous sulfate on alternate days
Number of subjects: 19
Study 31413088 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg iron as ferrous sulfate on alternate days
Number of subjects: 19
Study 31413088 — intervention group
Group type: COMPARATOR
Intervention: 100 mg iron as ferrous sulfate on consecutive days
Number of subjects: 19
Study 31413088 — intervention group
Group type: COMPARATOR
Intervention: 200 mg iron as ferrous sulfate on consecutive days
Number of subjects: 19
Study 31413088 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg iron as ferrous sulfate on alternate days vs 200 mg on consecutive days
Number of subjects: 19
Study 31413088 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal side effects
Number of subjects: 19
Study 29669086 — intervention group
Group type: COMPARATOR
Intervention: PA group (physical activity only)
Number of subjects: 60
Study 29669086 — intervention group
Group type: COMPARATOR
Intervention: PA + CBT‐P group (physical activity plus cognitive-behavioral therapy for pain)
Number of subjects: 60